Downloads: 1
Diff of
/clusters/3009knumclusters/clust_138.txt
[000000]
..
[c09aa8]
Switch to unified view
| a | b/clusters/3009knumclusters/clust_138.txt | ||
|---|---|---|---|
| 1 | Have severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients. |
||
| 2 | Has a known hypersensitivity to pembrolizumab or any of its excipients |
||
| 3 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 4 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 5 | Hypersensitivity to pembrolizumab or T-DM1 or any of their excipients |
||
| 6 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 7 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 8 | COHORT 1: Hypersensitivity to pembrolizumab or any of its excipients |
||
| 9 | COHORT 2: Hypersensitivity to pembrolizumab or any of its excipients |
||
| 10 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 11 | Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients. |
||
| 12 | Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients |
||
| 13 | Known hypersensitivity to any component of PVX-410, Hiltonol, Montanide, pembrolizumab, or excipients |
||
| 14 | Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipients |
||
| 15 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 16 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 17 | History of allergic reactions or hypersensitivity to pembrolizumab or any of its excipients |
||
| 18 | Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients |
||
| 19 | Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients |
||
| 20 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 21 | Hypersensitivity to pembrolizumab or any of its recipients |
||
| 22 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 23 | Has participated in any other pembrolizumab trial and has been treated with pembrolizumab. |
||
| 24 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 25 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 26 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 27 | Has a known hypersensitivity to pembrolizumab or any of its excipients |
||
| 28 | Hypersensitivity to pembrolizumab or any of its excipients. |
||
| 29 | Patient has a known hypersensitivity to any of the excipients of bavituximab or pembrolizumab or monoclonal antibody |
||
| 30 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 31 | Has serious hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients |
||
| 32 | Hypersensitivity to pembrolizumab or sunitinib or any of their excipients |
||
| 33 | Has hypersensitivity to pembrolizumab, epacadostat or any of its excipients |
||
| 34 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 35 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 36 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 37 | Hypersensitivity to pembrolizumab or lenvatinib or any of its excipients |
||
| 38 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 39 | Known hypersensitivity to pembrolizumab or any of its excipients |
||
| 40 | Has severe hypersensitivity (>= grade 3) to pembrolizumab or any of its excipients. |
||
| 41 | Has severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients. |
||
| 42 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 43 | Hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients |
||
| 44 | Had a severe hypersensitivity reaction to treatment with pembrolizumab or any of its excipients |
||
| 45 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 46 | Hypersensitivity to pembrolizumab or paricalcitol or any of its excipients. |
||
| 47 | Has hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients |
||
| 48 | Has a known history of hypersensitivity to pembrolizumab or any of its excipients. |
||
| 49 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 50 | Hypersensitivity to pembrolizumab or any of its excipients. |
||
| 51 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 52 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 53 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 54 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 55 | Hypersensitivity to pembrolizumab or any of its excipients. |
||
| 56 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 57 | Hypersensitivity to PBZ or any of its excipients |
||
| 58 | Hypersensitivity to pembrolizumab or any of its recipients |
||
| 59 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 60 | Has severe hypersensitivity to pembrolizumab or any of its excipients |
||
| 61 | Has hypersensitivity to either study drug or any of the excipients. |
||
| 62 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 63 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 64 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 65 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 66 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 67 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 68 | Has known hypersensitivity to pembrolizumab and/or epacadostat or any of their excipients |
||
| 69 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 70 | Known hypersensitivity to BGB324, pembrolizumab, or any of their excipients. |
||
| 71 | Hypersensitivity to ibrutinib or pembrolizumab or any of their excipients |
||
| 72 | Severe hypersensitivity to pembrolizumab or any of its excipients |
||
| 73 | Known hypersensitivity to pembrolizumab or any of its excipients |
||
| 74 | History of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or any of their excipients |
||
| 75 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 76 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 77 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 78 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 79 | Hypersensitivity to pembrolizumab |
||
| 80 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 81 | Hypersensitivity to pembrolizumab or lanreotide or any of their excipients |
||
| 82 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 83 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 84 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 85 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 86 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 87 | Has hypersensitivity to pembrolizumab or any of its excipients |
||
| 88 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 89 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 90 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 91 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 92 | Has hypersensitivity to pembrolizumab or any of its excipients |
||
| 93 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 94 | Known or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients) |
||
| 95 | Hypersensitivity to pembrolizumab or ibrutinib or any of their excipients |
||
| 96 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 97 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 98 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 99 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 100 | Hypersensitivity to bevacizumab, cyclophosphamide, pembrolizumab or any of its excipients |
||
| 101 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 102 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 103 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 104 | Hypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipients |
||
| 105 | Has a known hypersensitivity to pembrolizumab or any of its excipients |
||
| 106 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 107 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 108 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 109 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 110 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 111 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 112 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 113 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 114 | Hypersensitivity to pembrolizumab, vorinostat or any of its excipients |
||
| 115 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 116 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 117 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 118 | Hypersensitivity to pembrolizumab or any of its excipients. |
||
| 119 | Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients |
||
| 120 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 121 | Has hypersensitivity to pembrolizumab, docetaxel or any of its excipients |
||
| 122 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 123 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 124 | Has severe hypersensitivity (?Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipients |
||
| 125 | Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients. |
||
| 126 | Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab |
||
| 127 | REGISTRATION TO TREATMENT (STEP 1): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients |
||
| 128 | REGISTRATION TO TREATMENT (STEP 2): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients |
||
| 129 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 130 | Hypersensitivity to pembrolizumab or epacadostat or any of their excipients |
||
| 131 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 132 | Hypersensitivity to pembrolizumab, epacadostat or any of its excipients |
||
| 133 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 134 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 135 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 136 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 137 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 138 | Hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients; |
||
| 139 | Hypersensitivity to pembrolizumab, binimetinib, or any excipients of either drug |
||
| 140 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 141 | Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulation |
||
| 142 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 143 | Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients |
||
| 144 | Prior known allergic reaction to pembrolizumab or its excipients |
||
| 145 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 146 | Has a known severe hypersensitivity (> Grade 3) to pembrolizumab, its active substance and/or any of its excipients. |
||
| 147 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 148 | Has a known severe hypersensitivity to pembrolizumab, its active substance and/or any of its excipients |
||
| 149 | Known hypersensitivity to pembrolizumab or any of its insipients |
||
| 150 | Severe hypersensitivity to any pembrolizumab excipients |
||
| 151 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 152 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 153 | Known hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicin |
||
| 154 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 155 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 156 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 157 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 158 | Has known hypersensitivity to pembrolizumab or any of its excipients |
||
| 159 | Known hypersensitivity to pembrolizumab or any of its excipients. |
||
| 160 | Known allergy to pembrolizumab or any of its excipients. |
||
| 161 | Has severe hypersensitivity (? Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipients |
||
| 162 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 163 | Has severe hypersensitivity (Grade ?3) to pembrolizumab and/or any of its excipients |
||
| 164 | Has hypersensitivity to pembrolizumab or any of its excipients |
||
| 165 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 166 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 167 | Hypersensitivity to pembrolizumab, imatinib, or any of its excipients |
||
| 168 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 169 | Prior pembrolizumab |
||
| 170 | Hypersensitivity to pembrolizumab or any of it's excipients. |
||
| 171 | Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients. |
||
| 172 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 173 | Has hypersensitivity to pembrolizumab or any of its excipients |
||
| 174 | Patients with known hypersensitivity to pembrolizumab or any of its excipients |
||
| 175 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 176 | Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients. |
||
| 177 | Patients must not have a hypersensitivity to pembrolizumab or any of its excipients |
||
| 178 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 179 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 180 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 181 | Has hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab. |
||
| 182 | Hypersensitivity to pembrolizumab or any of its excipients |
||
| 183 | Hypersensitivity to pembrolizumab or any of its excipients |